{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T16:03:52Z","timestamp":1793549032815,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204308"],"award-info":[{"award-number":["82204308"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2024NSFSC2105"],"award-info":[{"award-number":["2024NSFSC2105"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2024qnGzn11"],"award-info":[{"award-number":["2024qnGzn11"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jconrel.2025.113762","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T12:41:48Z","timestamp":1745325708000},"page":"113762","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Slow intravenous infusion reduces the accelerated blood clearance of PEGylated liposomes by removing anti-PEG antibodies"],"prefix":"10.1016","volume":"382","author":[{"given":"Yaxin","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuguang","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jconrel.2025.113762_bb0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0168-3659(02)00462-5","article-title":"Accelerated clearance of PEGylated liposomes in rats after repeated injections","volume":"88","author":"Ishida","year":"2003","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113762_bb0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2006.01.005","article-title":"Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes","volume":"112","author":"Ishida","year":"2006","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2025.113762_bb0015","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jconrel.2006.08.001","article-title":"Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes","volume":"115","author":"Ishida","year":"2006","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.jconrel.2025.113762_bb0020","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1074-7613(01)00129-7","article-title":"Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens","volume":"14","author":"Martin","year":"2001","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113762_bb0025","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","article-title":"The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage","volume":"172","author":"Abu Lila","year":"2013","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2025.113762_bb0030","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.xphs.2023.11.001","article-title":"Treatment-induced and pre-existing anti-peg antibodies: prevalence, clinical implications, and future perspectives","volume":"113","author":"Gaballa","year":"2024","journal-title":"J. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.jconrel.2025.113762_bb0035","doi-asserted-by":"crossref","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","article-title":"Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies","volume":"15","author":"Chen","year":"2021","journal-title":"ACS Nano"},{"issue":"2","key":"10.1016\/j.jconrel.2025.113762_bb0040","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1021\/acs.molpharmaceut.3c00774","article-title":"Impact of anti-PEG IgM induced via the topical application of a cosmetic product containing PEG derivatives on the antitumor effects of PEGylated liposomal antitumor drug formulations in mice","volume":"21","author":"Gaballa","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.113762_bb0045","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jconrel.2023.01.012","article-title":"Investigation of anti-PEG antibody response to PEG-containing cosmetic products in mice","volume":"354","author":"Ibrahim","year":"2023","journal-title":"J. Control. Release"},{"issue":"11","key":"10.1016\/j.jconrel.2025.113762_bb0050","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.7150\/thno.22164","article-title":"Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes","volume":"8","author":"Hsieh","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2025.113762_bb0055","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jconrel.2023.09.003","article-title":"Accelerated blood clearance of PEGylated nanoparticles induced by PEG-based pharmaceutical excipients","volume":"363","author":"Miao","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113762_bb0060","first-page":"615","article-title":"A mouse model for studying the effect of blood anti-PEG IgMs levels on the <i>in vivo<\/i> fate of PEGylated liposomes","author":"El Sayed","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.113762_bb0065","first-page":"283","article-title":"Branched PEG-modification: a new strategy for nanocarriers to evade of the accelerated blood clearance phenomenon and enhance anti-tumor efficacy","author":"Liu","year":"2022","journal-title":"Biomaterials"},{"issue":"8","key":"10.1016\/j.jconrel.2025.113762_bb0070","article-title":"Poly(N-methyl-N-vinylacetamide): a strong alternative to PEG for lipid-based nanocarriers delivering siRNA","volume":"13","author":"Berger","year":"2024","journal-title":"Adv. Healthc. Mater."},{"issue":"27","key":"10.1016\/j.jconrel.2025.113762_bb0075","doi-asserted-by":"crossref","first-page":"32110","DOI":"10.1021\/acsami.3c02762","article-title":"Cleavable-branched polymer-modified liposomes reduce accelerated blood clearance and enhance photothermal therapy","volume":"15","author":"Sui","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2025.113762_bb0080","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jconrel.2024.12.029","article-title":"An anionic and proline-rich peptide prolonged blood circulation of liposomes and evaded accelerated blood clearance after repeated administration","volume":"378","author":"Zhang","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113762_bb0085","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jconrel.2023.07.031","article-title":"Poly(vinyl pyrrolidone) derivatives as PEG alternatives for stealth, non-toxic and less immunogenic siRNA-containing lipoplex delivery","volume":"361","author":"Berger","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113762_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124193","article-title":"Attenuated polyethylene glycol immunogenicity and overcoming accelerated blood clearance of a fully PEGylated dendrimer","volume":"659","author":"Kojima","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.113762_bb0095","article-title":"\u201cY-type\u201d PEG modified liposomes could eliminate the accelerated blood clearance (ABC) phenomenon and improved tumor therapy","volume":"32","author":"Liu","year":"2023","journal-title":"Appl. Mater. Today"},{"key":"10.1016\/j.jconrel.2025.113762_bb0100","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jconrel.2021.08.051","article-title":"High MW polyethylene glycol prolongs circulation of pegloticase in mice with anti-PEG antibodies","volume":"338","author":"Talkington","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113762_bb0105","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2019.06.007","article-title":"Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs","volume":"306","author":"Bavli","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113762_bb0110","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2019.08.017","article-title":"Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG","volume":"311-312","author":"McSweeney","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113762_bb0115","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.actbio.2023.08.052","article-title":"Pegloticase co-administered with high MW polyethylene glycol effectively reduces PEG-immunogenicity and restores prolonged circulation in mouse","volume":"170","author":"Li","year":"2023","journal-title":"Acta Biomater."},{"issue":"7","key":"10.1016\/j.jconrel.2025.113762_bb0120","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1039\/D2MH00380E","article-title":"Remote drug loading into liposomes via click reaction","volume":"9","author":"Zheng","year":"2022","journal-title":"Mater. Horiz."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113762_bb0125","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1021\/acs.molpharmaceut.4c00278","article-title":"Optimized enzyme-linked immunosorbent assay for anti-PEG antibody detection in healthy donors and patients treated with PEGylated liposomal doxorubicin","volume":"21","author":"Li","year":"2024","journal-title":"Mol. Pharm."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113762_bb0130","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/cam4.491","article-title":"Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients","volume":"4","author":"Golan","year":"2015","journal-title":"Cancer Med."},{"issue":"12","key":"10.1016\/j.jconrel.2025.113762_bb0135","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/jjco\/hyl109","article-title":"Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors","volume":"36","author":"Fujisaka","year":"2006","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113762_bb0140","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00280-021-04294-2","article-title":"Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma","volume":"88","author":"Liu","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.113762_bb0145","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jconrel.2021.11.042","article-title":"Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles<i> via<\/i> complement","volume":"341","author":"Senti","year":"2022","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.jconrel.2025.113762_bb0150","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1021\/acsnano.9b07218","article-title":"Premature drug release from polyethylene glycol (PEG)-coated liposomal doxorubicin <i>via<\/i> formation of the membrane attack complex","volume":"14","author":"Chen","year":"2020","journal-title":"ACS Nano"},{"issue":"23","key":"10.1016\/j.jconrel.2025.113762_bb0155","doi-asserted-by":"crossref","first-page":"10107","DOI":"10.1021\/acs.nanolett.1c03946","article-title":"Facile separation of PEGylated liposomes enabled by anti-PEG scFv","volume":"21","author":"Tang","year":"2021","journal-title":"Nano Lett."},{"issue":"11","key":"10.1016\/j.jconrel.2025.113762_bb0160","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nri2849","article-title":"The importance of natural IgM: scavenger, protector and regulator","volume":"10","author":"Ehrenstein","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113762_bb0165","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ejps.2011.11.014","article-title":"Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats","volume":"45","author":"Ma","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113762_bb0170","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00280-011-1664-2","article-title":"Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients","volume":"69","author":"La-Beck","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.113762_bb0175","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","volume":"154","author":"Kozma","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113762_bb0180","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jconrel.2005.04.003","article-title":"Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes","volume":"105","author":"Ishida","year":"2005","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.jconrel.2025.113762_bb0185","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z","article-title":"Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma","volume":"89","author":"Lyass","year":"2000","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.jconrel.2025.113762_bb0190","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1211\/jpp.60.12.0011","article-title":"Repeated injection of pegylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase","volume":"60","author":"Cui","year":"2008","journal-title":"J. Pharm. Pharmacol."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113762_bb0195","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40259-013-0070-1","article-title":"Pegylated liposomal doxorubicin: a guide to its use in various malignancies","volume":"27","author":"Lyseng-Williamson","year":"2013","journal-title":"BioDrugs"},{"key":"10.1016\/j.jconrel.2025.113762_bb0200","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jconrel.2023.06.027","article-title":"Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route","volume":"360","author":"Takata","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113762_bb0205","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jconrel.2022.12.005","article-title":"The mechanisms of anti-PEG immune response are different in the spleen and the lymph nodes","volume":"353","author":"Grenier","year":"2023","journal-title":"J. Control. Release"},{"issue":"21","key":"10.1016\/j.jconrel.2025.113762_bb0210","doi-asserted-by":"crossref","first-page":"10661","DOI":"10.1021\/acs.analchem.6b03109","article-title":"Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals","volume":"88","author":"Chen","year":"2016","journal-title":"Anal. Chem."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2025.113762_bb0215","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ijpharm.2012.07.049","article-title":"Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs","volume":"436","author":"Suzuki","year":"2012","journal-title":"Int. J. Pharm."},{"issue":"11","key":"10.1016\/j.jconrel.2025.113762_bb0220","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/jps.2600751104","article-title":"Man versus beast: pharmacokinetic scaling in mammals","volume":"75","author":"Mordenti","year":"1986","journal-title":"J. Pharm. Sci."},{"issue":"587","key":"10.1016\/j.jconrel.2025.113762_bb0225","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba6322","article-title":"Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection","volume":"13","author":"Nishio","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113762_bb0230","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jconrel.2025.113762_bb0235","doi-asserted-by":"crossref","DOI":"10.1186\/ar4500","article-title":"Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113762_bb0240","doi-asserted-by":"crossref","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res. Ther."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925003827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925003827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:00:39Z","timestamp":1777870839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925003827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":48,"alternative-id":["S0168365925003827"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113762","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Slow intravenous infusion reduces the accelerated blood clearance of PEGylated liposomes by removing anti-PEG antibodies","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113762","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113762"}}